Therapeutic Strategy for BRAF-Mutated Cancer

BRAF mutation is occurred in about 8% of human malignancy, including 40-60% in malignant melanoma, 50% in thyroid papillary cancer, 10% in colorectal cancer, and a few percent of non-small cell lung cancer. Activated mutation of BRAF is mainly p. V600E mutation. BRAF inhibitors were initially developed in malignant melanoma. In a recent few years, BRAF inhibitor-based therapy has been developed also in other cancers such as lung cancer and colorectal cancer. I herein describe the current status of development of new therapeutic strategies for S/MF-mutated cancer, particularly BRAF-targeting therapy.